학술논문
Clinical Outcomes of HER2-Negative Metastatic Breast Cancer Patients in Italy in the Last Decade: Results of the GIM 13-AMBRA Study.
Document Type
Article
Author
Cazzaniga, Marina Elena; Pronzato, Paolo; Amoroso, Domenico; Bernardo, Antonio; Biganzoli, Laura; Bisagni, Giancarlo; Blasi, Livio; Bria, Emilio; Cognetti, Francesco; Crinò, Lucio; De Laurentiis, Michelino; Del Mastro, Lucia; De Placido, Sabino; Beano, Alessandra; Ferraù, Francesco; Foladore, Silva; Forcignanò, Rosachiara; Gamucci, Teresa; Garrone, Ornella; Gennari, Alessandra
Source
Subject
*CONFIDENCE intervals
*ONCOGENES
*METASTASIS
*ANTINEOPLASTIC agents
*HYDROCARBONS
*TREATMENT effectiveness
*DESCRIPTIVE statistics
*RESEARCH funding
*CELL lines
*BEVACIZUMAB
*ODDS ratio
*PROGRESSION-free survival
*BREAST tumors
*LONGITUDINAL method
*OVERALL survival
*EVALUATION
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
Language
ISSN
2072-6694
Abstract
Simple Summary: Breast cancer is one of the most common oncological diseases among women in Western Countries and Italy as well. GIM 13-AMBRA is a patient journey study regarding how the prognosis of metastatic breast cancer patients has changed in the last decades as a result of the introduction of new drugs in clinical practice. This study also provides information regarding the different natural histories of breast cancer according to the presence or absence of hormone receptors and HER2 receptors. GIM 13-AMBRA is a longitudinal cohort study aimed at describing therapeutic strategies and the relative outcome parameters in 939 HER2-ve MBC patients. Taxanes–based regimens, or taxanes + targeted agents, mainly Bevacizumab, were the preferred first choice in both Luminal (30.2%) and TNBC (33.3%) patients. The median PFS1 was 12.5 months (95% CI 16.79–19.64), without any significant difference according to subtypes, while the median Time to first Treatment Change (TTC1) was significantly lower in TNBC patients (7.7 months—95% CI 5.7–9.2) in comparison to Luminal A (13.2 months, 95% CI 11.7–15.1) and Luminal B patients (11.8 months, 95% CI 10.3–12.8). PFS2 was significantly shorter in TNBC patients (5.5 months, 95% CI 4.3–6.5 vs. Luminal A—9.4, 95% CI 8.1–10.7, and Luminal B—7.7 95% CI 6.8–8.2, F-Ratio 4.30, p = 0.014). TTC2 was significantly lower in patients with TNBC than in those with the other two subtypes. The median OS1 was 35.2 months (95% CI 30.8–37.4) for Luminal A patients, which was significantly higher than that for both Luminal B (28.9 months, 95% CI 26.2–31.2) and TNBC (18.5 months, 95% CI 16–20.1, F-ratio 7.44, p = 0.0006). The GIM 13—AMBRA study is one of the largest collections ever published in Italy and provides useful results in terms of time outcomes for first, second, and further lines of treatment in HER2- MBC patients. [ABSTRACT FROM AUTHOR]